Target intelligence / Profile preview

Semaphorin-6B (SEMA6B)

Target
SEMA6B
Molecular classification
Receptor, Signaling protein, Type I transmembrane glycoprotein, Semaphorin family
01

Overview

Semaphorin-6B is a member of the semaphorin family, specifically the class 6 transmembrane semaphorins, and functions primarily as a cell-surface repellent influencing axon guidance, cell migration, and neural circuit development. It contains characteristic sema and PSI (plexin-semaphorin-integrin) domains, and is highly expressed in heart and brain tissues but also found throughout the body at lower levels. Semaphorin-6B has a well-documented role in neurodevelopment, especially in the guidance of mossy fibers in the hippocampus, and interacts with plexin family receptors, particularly Plexin A2 and A4. Genetic variants, including truncating and missense mutations, have been directly linked to progressive myoclonic epilepsy and may be relevant in other neurodevelopmental and oncologic diseases

Other names
Semaphorin 6BSEMA6BSEMANSEMAZUNQ1907/PRO4353Sema ZsemaZSEMA-VIBSEM-SEMA-ZSemaphorin-ZSema VIbsemaphorin Zsemaphorin VIBEPM11SEM-SEMA-Ysema domain, transmembrane domain (TM) and cytoplasmic domain(semaphorin) 6Bsemaphorin-6Ba
02

Mechanism of action

Not fully established for drugs; retinoic acid modulates SEMA6B via RXR/PPAR-mediated transcriptional repression

03

Biological functions

Axon guidanceCell migrationSynaptogenesisDendritic spine formationNervous system developmentSignal transduction
04

Disease associations

Epilepsy (Progressive myoclonic epilepsy 11; dominant, non-syndromic intellectual disability)Cancer (implicated in tumor differentiation and metastasis in gastric, breast, and glioblastoma cancer)Neurodevelopmental disordersOther: Acts as a receptor for P. sordellii TcsL toxin, relevant for microbial infection
05

Safety considerations

Not specifically documented for drug targetingOverexpression or mutations produce neurodevelopmental defectsMay lead to enhanced seizure susceptibility or malignant transformationSuggests possible risk if targeted indiscriminately
06

Interacting drugs

retinoic acid
07

Biomarkers

Disease-causing variants used as biomarkers for autosomal dominant epilepsy (missense and truncating mutations in SEMA6B)

Beyond the preview

Go deeper on Semaphorin-6B (SEMA6B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Semaphorin-6B (SEMA6B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call